SAN DIEGO--(BUSINESS WIRE)--MBrace Therapeutics, Inc. (“MBrace”), a clinical-stage biopharmaceutical company devoted to improving the lives of cancer patients through the development of antibody-drug ...
Increased specific killing of cancer cells in vitro by the combination of NKX101 and cetuximab, supporting use for combination in solid tumors SOUTH SAN FRANCISCO, Calif., April 17, 2023 (GLOBE ...
Celcuity to Present Preclinical Data for Gedatolisib at the 2023 San Antonio Breast Cancer Symposium
MINNEAPOLIS, Dec. 01, 2023 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results